Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Price Target at $11.00

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have received an average recommendation of “Buy” from the seven analysts that are covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $11.00.

Several equities analysts have commented on AQST shares. JMP Securities reiterated a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a report on Friday, December 20th. Leerink Partners upped their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Finally, Cantor Fitzgerald assumed coverage on Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price objective on the stock.

Institutional Investors Weigh In On Aquestive Therapeutics

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its holdings in Aquestive Therapeutics by 5.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company’s stock valued at $8,306,000 after acquiring an additional 90,543 shares in the last quarter. State Street Corp raised its stake in shares of Aquestive Therapeutics by 52.1% in the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock valued at $7,454,000 after purchasing an additional 512,682 shares in the last quarter. Blue Owl Capital Holdings LP lifted its position in Aquestive Therapeutics by 30.3% in the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock worth $2,964,000 after purchasing an additional 265,000 shares during the period. Janney Montgomery Scott LLC boosted its stake in Aquestive Therapeutics by 6.6% during the fourth quarter. Janney Montgomery Scott LLC now owns 984,485 shares of the company’s stock worth $3,505,000 after buying an additional 61,200 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Aquestive Therapeutics in the 2nd quarter valued at $594,000. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Trading Up 3.5 %

Aquestive Therapeutics stock opened at $3.21 on Wednesday. Aquestive Therapeutics has a 1-year low of $2.24 and a 1-year high of $6.23. The firm’s fifty day simple moving average is $3.93 and its 200-day simple moving average is $4.19. The company has a market capitalization of $292.68 million, a P/E ratio of -7.13 and a beta of 2.71.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $13.54 million during the quarter, compared to the consensus estimate of $12.69 million. During the same period in the prior year, the company earned ($0.03) earnings per share. On average, equities research analysts predict that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.